MCRR Refugees Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : MCRR Refugees

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: WallStBum who wrote (57)	7/6/1998 1:38:00 PM
From: Claudia Benson	Read Replies (3) of 582

Dax, I don't have historical pricing, but it was ~ 60 cents last week. Here's today's news release. This was never mentioned on the MCRR board. Got the original information back in Sept, from WAACO. That 2 dollar word created all the whoopla today. ;-) Check out the CYGS thread, you'll get some realistic information, w/o the usual hype. Maybe Dr Epstein will give us his take on this. Claudia...ps What is the difference between "in vivo" and "in vitro"? CSI Researchers Express ssDNA in Vivo HOUSTON--(BW HealthWire)--July 6, 1998--Cryogenic Solutions Inc. (OTC BB:CYGS - news) announced the expression of sequence specific oligodeoxyribonucleotides from a ribonucleic acid expression vector. This in vivo expression of single-stranded DNA (ssDNA) that is complementary to an RNA template encoded in a vector was accomplished under a sponsored research agreement by CSI. The option of having flanking regions present or absent in the expressed ssDNA product is an additional useful property of this work. CSI holds the patent rights of this and related technology developed under the sponsored research agreement. This press release contains no forward looking statements and is therefore in no need of protection under the Securities Litigation Reform Act of 1995. Investment in the securities of the company is imprudent and not recommended if the press release as written is not clearly understood by the investor. Background information available on the website <www.biogenix.com> email -- cygs@wt.net For additional information please call 713/780-1399, 9-4 CST Investor relations -- Dell Gibson, VP Biotech details -- Craig Tomlinson, PhD

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next